Share

August 2016; 3 (4) ArticleOpen Access

Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis

Benjamin J. Murdock, Diane E. Bender, Samy R. Kashlan, Claudia Figueroa-Romero, Carey Backus, Brian C. Callaghan, Stephen A. Goutman, Eva L. Feldman
First published June 1, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000242
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1534

Share

Article Information

vol. 3 no. 4 e242
DOI: 
https://doi.org/10.1212/NXI.0000000000000242
PubMed: 
27308304
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 1, 2016
  • Accepted in final form March 24, 2016
  • First Published June 1, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Benjamin J. Murdock, PhD*,
    2. Diane E. Bender, PhD*,
    3. Samy R. Kashlan, MD,
    4. Claudia Figueroa-Romero, PhD,
    5. Carey Backus, BS,
    6. Brian C. Callaghan, MD,
    7. Stephen A. Goutman, MD and
    8. Eva L. Feldman, MD, PhD
  1. Benjamin J. Murdock, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Served as a temporary grant writer for the American Neurological Association. Compensation was ≤ $1000.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) CReATe Consortium: examination the role of blood-borne NK cells in ALS pathogenesis.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Diane E. Bender, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Samy R. Kashlan, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Claudia Figueroa-Romero, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Katherine Rayner Fund A. Alfred Taubman Medical Research Institute

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Carey Backus, BS,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent: Trk C antibody, produced at UCSF

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Brian C. Callaghan, MD,
    7. Scientific Advisory Boards:

    1. Consultant and scientific advisory board member on a PCORI grant

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1) American Academy of Neurology, travel 2) World Federation of Neurology, travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant and scientific advisory board member on a PCORI grant

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. 1.ALS Association, certify centers 2.Advance Medical, patient consultation service 3.Honoraria from the British Medical Journal

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Impeto Medical Inc.

    Research Support, Government Entities:

    1. NIH K23 NS079417-01, PI, 5 year award

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Consultant for medical legal case

  7. Stephen A. Goutman, MD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Neuralstem Protocol # NS2012-3

    Research Support, Government Entities:

    1. (1) CDC/ATSDR, Contract # 200-2013-56856, Co-Investigator, 2013 to present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Eva L. Feldman, MD, PhD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Centers for Disease Control, Contract #200-2013-56856,PI, 09/01/2013-08/31/2017, (2) NIH (Prime: Emory University), RO1 NS077982, PI,09/02/2012-07/31/2016 (3) NIH/NINDS, T32 NS07222, PI, 07/01/2012-06/30/2017 (4) NIH, 1DP3DK094292, PI, 09/30/2011-09/29/2016 (5) NIH-NIDDK (CDC Contract #200-2010-35171; Prime: Wake Forest University (WFUHS 30225)), Site PI,09/30/2010-09/29/2015 (6) NIH/NIDDK, 1 R24 082841, PI, 04/01/2010- 03/31/2016 (7) NIH/NINDS, R01 NS08230401A1, Co-I, 05/01/2014-04/30/2019 (8) NIH (Prime; Direct-University of Colorado, Denver), PI, 06/01/2013-05/31/2017 (9) NIH/NINDS, K23 NS079417, Sponsor, 07/01/13-06/30/18

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Novo Nordisk Foundation, NNF14SA0006, PI, (2) Juvenile Diabetes Research Foundation, Sponsor, (3)Juvenile Diabetes Research Foundation, PI, (4) US-Israel Binational Science Foundation, PI, (5) American Diabetes Association, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (B.J.M., D.E.B., S.R.K., C.F.-R., C.B., B.C.C., S.A.G., E.L.F.) and A. Alfred Taubman Medical Research Institute (E.L.F.), University of Michigan, Ann Arbor.
  1. Correspondence to Dr. Feldman: efeldman{at}umich.edu
View Full Text

Article usage

Article usage: June 2016 to April 2023

AbstractFullPdfSource
Jun 201624126438Highwire
Jun 201605025pmc
Jul 2016781119Highwire
Jul 201604421pmc
Aug 201619131428Highwire
Aug 201605119pmc
Sep 201655486Highwire
Sep 201603916pmc
Oct 201660997Highwire
Oct 201602715pmc
Nov 201638896Highwire
Nov 20160229pmc
Dec 201626269Highwire
Dec 20160245pmc
Jan 201739106Highwire
Jan 20170345pmc
Feb 201729159Highwire
Feb 20170363pmc
Mar 201723122Highwire
Mar 20170467pmc
Apr 201715100Highwire
Apr 201733639pmc
May 20171738Highwire
May 201774248pmc
Jun 2017642Highwire
Jun 201782931pmc
Jul 20171799Highwire
Jul 201773138pmc
Aug 20171871Highwire
Aug 201733942pmc
Sep 20171214Highwire
Sep 2017154353pmc
Oct 20171874Highwire
Oct 2017214055pmc
Nov 20171663Highwire
Nov 2017122730pmc
Dec 20170127Highwire
Jan 201823209Highwire
Feb 20181152Highwire
Mar 201803115Highwire
Apr 201803073Highwire
Apr 201863034pmc
May 201812305Highwire
Jun 2018014010Highwire
Jun 201892229pmc
Jul 201811037Highwire
Aug 20182513Highwire
Aug 201872020pmc
Sep 20181421Highwire
Oct 201818412Highwire
Nov 201811005Highwire
Dec 201801743Highwire
Jan 201941501Highwire
Feb 201991986Highwire
Mar 2019613113Highwire
Apr 2019312113Highwire
May 2019118612Highwire
Jun 20197708Highwire
Jul 2019813711Highwire
Aug 2019521113Highwire
Sep 2019120314Highwire
Oct 2019722816Highwire
Nov 2019251634Highwire
Dec 20192410113Highwire
Jan 202031295Highwire
Feb 2020134810Highwire
Mar 2020956018Highwire
Apr 202026629Highwire
May 2020569316Highwire
Jun 2020335214Highwire
Jul 2020136019Highwire
Aug 2020433513Highwire
Sep 2020279218Highwire
Oct 2020837623Highwire
Nov 2020218311Highwire
Dec 2020418413Highwire
Jan 2021518728Highwire
Feb 2021423527Highwire
Mar 2021919420Highwire
Apr 2021522217Highwire
May 2021419713Highwire
Jun 2021519913Highwire
Jul 2021217914Highwire
Aug 202132258Highwire
Sep 202141825Highwire
Oct 202179627Highwire
Nov 202158818Highwire
Dec 202139113Highwire
Jan 20221628Highwire
Feb 20226309Highwire
Mar 202284622Highwire
Apr 202241169Highwire
May 202263714Highwire
Jun 202266223Highwire
Jul 20227367Highwire
Aug 20229358Highwire
Sep 202244111Highwire
Oct 202274218Highwire
Nov 2022108630Highwire
Dec 202238115Highwire
Jan 202376114Highwire
Feb 202364020Highwire
Mar 202324125Highwire
Apr 202343928Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles